Bupropion extended release efficacy
Pro Research Analysisby 
Searched over 200M research papers
Bupropion Extended Release Efficacy in Major Depressive Disorder
Several studies have shown that bupropion extended release (XL) is effective for treating major depressive disorder (MDD). In a large randomized trial, bupropion XL was found to be non-inferior to escitalopram in reducing depression symptoms over 8 weeks, with similar response and remission rates between the two drugs . Other research confirms that bupropion XL is as effective as other antidepressants for depression, including in elderly patients and those with symptoms like low energy, reduced pleasure, and lack of interest 245. In patients with MDD who specifically had decreased energy, pleasure, and interest, bupropion XL led to greater improvements than placebo, with higher response and remission rates .
Comparative Efficacy and Tolerability
When compared directly to escitalopram, bupropion XL showed similar antidepressant efficacy but had a better profile regarding sexual side effects, with significantly fewer patients experiencing sexual dysfunction 19. Compared to venlafaxine XR, bupropion XL did not show statistically significant improvement over placebo in one study, but both active treatments improved patient functioning and were generally well tolerated . Bupropion XL is also associated with a lower risk of somnolence, sexual dysfunction, and weight gain compared to some other antidepressants .
Efficacy in Special Populations
Bupropion XL has demonstrated effectiveness in elderly patients with depression, showing significant improvements in motivation, energy, and life satisfaction compared to placebo, with mild to moderate side effects . In children and adolescents with depressive disorders, bupropion XL led to significant symptom improvement over 12 weeks, with nearly half of patients responding to treatment and a generally good safety profile .
Other Indications: ADHD and Substance Use Disorders
Beyond depression, bupropion XL has shown efficacy as a nonstimulant treatment for adult ADHD, with a higher responder rate than placebo and sustained benefits throughout the day . In combination with naltrexone, bupropion XL has also been studied for methamphetamine use disorder, where it produced a higher response rate than placebo, though the overall response was modest .
Conclusion
Bupropion extended release is an effective and well-tolerated option for major depressive disorder, with efficacy comparable to other antidepressants and some advantages in side effect profile, especially regarding sexual function and weight gain. It is also effective in elderly patients, children, and adolescents with depression, and has demonstrated benefits in adult ADHD and as part of combination therapy for substance use disorders 1234+5 MORE.
Sources and full results
Most relevant research papers on this topic